Elizabeth Odette likes to stay busy, and she has welcomed opportunities to take on several complex litigation cases at her firm, Lockridge Grindal Nauen. In recent years, Odette has participated in nine jury trials across the country involving failure-to-warn claims related to osteonecrosis of the jaw in people taking the drugs Aredia and Zometa, manufactured by Novartis Pharmaceuticals Corp. Four of the trials occurred in the last year in federal courts, and in all four, the juries returned verdicts for plaintiffs ranging from $225,000 to $2.2 million.